EU snubs extra 300 mln J&J, Astra shots in bet on Pfizer-source
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
TUESDAY, MAY 17, 2022
TUESDAY, MAY 17, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
EU snubs extra 300 mln J&J, Astra shots in bet on Pfizer-source

Coronavirus chronicle

Reuters
21 April, 2021, 07:40 pm
Last modified: 21 April, 2021, 07:40 pm

Related News

  • EU needs a few more days for next sanctions package on Russia - Germany
  • EU braces for storm as Ukraine fallout cascades in economy
  • EU wants Bangladesh to quickly amend EPZ Labour Act
  • China voices discontent with EU-Japan position on Senkaku islands
  • EU's Borrell says coordinator trip to Iran was positive

EU snubs extra 300 mln J&J, Astra shots in bet on Pfizer-source

The decision is the latest sign Brussels is looking to distance itself from AstraZeneca amid simmering tensions after the drugmaker slashed its delivery targets due to production problems

Reuters
21 April, 2021, 07:40 pm
Last modified: 21 April, 2021, 07:40 pm
The EU flag is reflected in a drop on a syringe needle in this illustration Photo: Reuters
The EU flag is reflected in a drop on a syringe needle in this illustration Photo: Reuters

The European Union won't take up an extra 300 million doses of AstraZeneca and Johnson & Johnson Covid-19 vaccines that it has secured as options under existing contracts, a senior EU official told Reuters.

The decision is the latest sign Brussels is looking to distance itself from AstraZeneca amid simmering tensions after the drugmaker slashed its delivery targets due to production problems.

It is also further evidence the bloc is sidelining vaccines that have been linked with a very rare, but potentially fatal side effect, and is confident current suppliers - led by Pfizer/BioNTech - will deliver enough doses to inoculate at least 70% of EU adults by the end of the summer.

Recently, the EU has sought to buy more shots from Pfizer and its partner BioNTech, stepping up its bets on the messenger RNA (mRNA) technology they use, as opposed to the viral vector technology used by AstraZeneca and J&J.

The 27-nation bloc has a contract for a total of 400 million doses with J&J, of which only 200 million have already been ordered, and a separate contract with AstraZeneca for 400 million shots, of which only 300 million have been bought.

"There is no need to exercise the options" for the extra doses, the official who is directly involved in talks with vaccine makers said.

EU governments are under pressure to accelerate vaccination programmes, which have lagged those in Britain and the United States due to supply delays and safety concerns, to help tame a third wave of infections.

A spokesman for the European Commission, which coordinates talks with vaccine makers, said options can be exercised at any time, but declined further comment.

The official, who asked not to be named because the matter is confidential, said discussions were ongoing about further supplies for booster shots and coronavirus variants, and it was premature to rule AstraZeneca and J&J out of future contracts.

But the technology on which their shots are based is less appealing than other vaccine platforms, the official said. Last week, Italian newspaper La Stampa said the EU would not renew contracts with the companies when they expire.

Both vaccines have been linked to very rare cases of blood clots, which have led to temporary suspensions of their rollout in Europe, although the EU drugs regulator has concluded the benefits of both vaccines outweigh the risks.

Both companies have also had production problems, with AstraZeneca in particular slashing its EU supply targets by two thirds to 100 million doses by the end of June, sparking fury in Brussels.

The EU official said AstraZeneca's supply problems had convinced EU negotiators not to seek the optional doses from the company. Under the contract, that option should have been exercised by early March, although the EU could have still tried to order more doses after then.

A spokesman for AstraZeneca declined to comment.

The EU official added that, in the case of J&J, initial safety concerns about viral vector technology had pushed negotiators not to seek optional doses and might also prevent talks for a new contract.

A spokeswoman for J&J declined to comment.

The EU's existing Covid-19 vaccine contracts have been widely criticised for being too lenient with companies because they set quarterly rather than monthly delivery targets, although other countries have done the same.

Last week, the Commission said it was starting talks with Pfizer and BioNTech to buy up to 1.8 billion vaccine doses for the coming years under a new contract with monthly targets, as it prepares for the possible spread of new virus variants and potential waning protection from initial shots.

The EU source said the new contract with Pfizer and BioNTech was expected to meet a large share of the EU's demand in 2022 and 2023.

The bloc, with a population of nearly 450 million, has already ordered 600 million Pfizer/BioNTech vaccines for this year. It has also bought 310 million doses from Moderna to be delivered this year, and has an option to buy another 150 million doses next year. Moderna also uses mRNA technology.

The EU also has contracts with CureVac and Sanofi, but neither of them has completed clinical trials. 

Top News

AstraZeneca Covid-19 Vaccine / Pfizer Covid-19 Vaccine / Johnson & Johnson Covid-19 Vaccine / EU

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
    Dollar price crosses Tk100 in open market 
  • Govt fixes tolls for Padma Bridge
    Govt fixes tolls for Padma Bridge
  • Photo: PID
    Prioritise dev projects, spend wisely: PM Hasina 

MOST VIEWED

  • People watch a TV broadcasting a news report on the coronavirus disease (Covid-19) outbreak in North Korea, at a railway station in Seoul, South Korea on 17 May 2022. Photo: Reuters.
    N Korea Covid outbreak could have 'devastating' impact on human rights, UN says
  • Two women hug at a closed street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 16, 2022. REUTERS/Aly Song
    Shanghai achieves 'zero Covid' status but normal life is weeks away
  • People wearing protective face masks commute amid concerns over the new coronavirus disease (COVID-19) in Pyongyang, North Korea March 30, 2020, in this photo released by Kyodo. Picture taken March 30, 2020. Mandatory credit Kyodo/via REUTERS
    N Korea mobilises army, steps up tracing amid Covid wave
  • Customers wait in front of a restaurant in Beijing, China April 15, 2022. REUTERS/Tingshu Wang/Files
    China's economy skids as lockdowns hit factories, retailers
  • A medical worker in a protective suit collects a swab from a resident at a makeshift nucleic acid testing site inside a residential compound under lockdown, amid the coronavirus disease (COVID-19) outbreak in Shanghai, China April 14, 2022. REUTERS/Xihao Jiang
    Shanghai aims for return to normal life from 1 June
  • South Korea's new President Yoon Suk-yeol signs a document as he works at the new Presidential office in Seoul, South Korea, May 10, 2022. Yonhap via REUTERS/File Photo
    S Korea says it will spare no effort to help North Korea amid Covid outbreak

Related News

  • EU needs a few more days for next sanctions package on Russia - Germany
  • EU braces for storm as Ukraine fallout cascades in economy
  • EU wants Bangladesh to quickly amend EPZ Labour Act
  • China voices discontent with EU-Japan position on Senkaku islands
  • EU's Borrell says coordinator trip to Iran was positive

Features

Despite Bangladesh having about 24,000 km of waterways, only a few hundred kilometres are covered by commercial launch services. Photo: Saad Abdullah

Utilising waterways: When common home-goers show the way

5h | Panorama
Illustration: TBS

How Putin revived Nato

7h | Panorama
The reception is a volumetric box-shaped room that has two glass walls on both the front and back ends and the other two walls are adorned with interior plants, wood and aluminium screens. Photo: Noor-A-Alam

The United House: Living and working inside nature

7h | Habitat
Pcycle team members at a waste management orientation event. Photo: Courtesy

Pcycle: Turning waste from bins into beautiful crafts

8h | Panorama

More Videos from TBS

Can your coworker be your closest friend?

Can your coworker be your closest friend?

8h | Videos
The mystery behind Pyramid

The mystery behind Pyramid

8h | Videos
Finland, Sweden decide to join NATO

Finland, Sweden decide to join NATO

20h | Videos
Where you can swim for Tk5

Where you can swim for Tk5

22h | Videos

Most Read

1
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

2
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

3
Impact of falling taka against US dollar
Banking

Taka losing more value as global currency market volatility persists

4
Govt tightens belt to relieve reserve
Economy

Govt tightens belt to relieve reserve

5
Union Capital asked to return Tk100cr FDR to BATBC 
Banking

Union Capital asked to return Tk100cr FDR to BATBC 

6
How Bangladesh can achieve edible oil self-sufficiency with local alternatives
Bazaar

How Bangladesh can achieve edible oil self-sufficiency with local alternatives

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab